针对受体相互作用蛋白激酶1的向降解,以调节亡途径
Hiroyuki Inuzuka1, Chao Qian2, Yihang Qi1
1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States.
我们开发了MS2031,一种向的PROTAC疗法,用于降低受体相互作用蛋白激酶1 (RIPK1). 这种方法有效地抑制了亡信号传递,为治疗与RIPK1失调相关的疾病提供了潜力.
科学领域:
- 细胞生物学 细胞生物学
- 细胞死亡的分子机制
- 药物发现 药物发现
背景情况:
- 亡是一种受调节的细胞死亡途径,对免疫和组织健康至关重要.
- 死体亡的失调与癌症和神经退行等疾病有关.
- 受体相互作用蛋白激酶1 (RIPK1) 是一个关键的调节器和治疗亡的目标.
研究的目的:
- 制定一个有针对性的策略来抑制RIPK1.1.
- 调查一种针对RIPK1的新型蛋白质溶解向金氏体 (PROTAC) 在降解RIPK1和调节亡中的有效性.
主要方法:
- 设计和合成MS2031,一个PROTAC分子,将RIPK1结合剂与VHL配体连接起来.
- 招募CRL2VHL E3无素结合酶复合物用于RIPK1.1.的蛋白质体降解.
- 在癌症细胞系中对RIPK1蛋白减少和亡途径调节的评估 (HT-29,T47D).
主要成果:
- 在纳米分子度下,MS2031实现了强大的RIPK1蛋白降解.
- MS2031有效调节了治疗细胞中的亡信号通路.
- 证明了RIPK1蛋白的有针对性的降解.
结论:
- MS2031是一种高效的RIPK1向PROTAC.
- 通过MS2031向RIPK1降解显示了RIPK1介导疾病的治疗潜力.
- 这一策略提供了一种新的方法来控制疾病背景下的亡.
更多相关视频
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
06:12Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
相关概念视频
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
The Extrinsic Apoptotic Pathway
Regulation of the Unfolded Protein Response
PI3K/mTOR/AKT Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
